Targeting IL-22RA1 with temtokibart: A novel approach in atopic dermatitis: Phase 2a monotherapy study results
Journal of Allergy and Clinical Immunology · 2026-03 · 157 (3) · 666-676
DOI: 10.1016/j.jaci.2025.08.034 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Journal of Allergy and Clinical Immunology, 2026-03. Verfasst von Diamant Thaçi und 12 weiteren Autor:innen. Beteiligte Einrichtung: Institute and Comprehensive Center for Inflammation Medicine, University of Lübeck, Lübeck, Germany. Electronic address: diamant.thaci@uksh.de. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Receptors, Interleukin, Antibodies, Monoclonal, Humanized, Antibodies, Monoclonal. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: LEO Pharma A/S, LEO Pharma Research Foundation.
Abstract (Originalsprache)
BACKGROUND: Atopic dermatitis (AD) is a chronic inflammatory skin disease in which increased IL-22 expression contributes to epidermal hyperplasia and barrier defects. Temtokibart is a monoclonal antibody targeting IL-22RA1 (IL-22 receptor subunit alpha-1), blocking the signaling of IL-22 and potentially also of IL-20 and IL-24. OBJECTIVE: We evaluated the efficacy and safety of temtokibart in adults with moderate-to-severe AD. METHODS: In this phase 2a study (NCT04922021), 58 adults were randomized 1:1 to subcutaneous temtokibart 450 mg or placebo every 2 weeks for 16 weeks, with an additional dose (450 mg) at week 1, followed by additional 16 weeks of safety follow-up. The primary end point was change in Eczema Area Severity Index (EASI) from baseline to week 16. Biomarkers in serum, including IL-22, were analyzed as an exploratory end point. RESULTS: Mean change in EASI from baseline to week 16 was significantly greater for temtokibart compared to placebo (-15.3 vs -3.5; P = .003), corresponding to 65.4% and 19.7% improvement for temtokibart and placebo groups, respectively. At week 16, greater proportions of patients receiving temtokibart relative to placebo obtained EASI-75 (41.6% vs 13.7%; P = .011), EASI-90 (30.8% vs 3.5%; P = .003), and EASI-100 (20.9% vs 0%; P = .006). Treatment with temtokibart was well tolerated, and no safety signals were observed. Further, temtokibart treatment was associated with a general reduction of systemic inflammatory proteins. CONCLUSIONS: This proof-of-concept study demonstrates that targeting the IL-22 pathway with temtokibart is clinically effective with a favorable safety profile.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute and Comprehensive Center for Inflammation Medicine, University of Lübeck, Lübeck, Germany. Electronic address: diamant.thaci@uksh.de.
- First OC Dermatology Research, Fountain Valley, Calif.
- The Lynde Institute for Dermatology and Lynderm Research, Markham, Ontario, Canada; Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
- Department of Dermatology, University of Rzeszow, Rzeszow, Poland.
- AllerVie Health-Alabama Allergy and Asthma Center, Birmingham, Ala.
- Division of Allergy and Immunology, Department of Dermatology, Venereology and Allergy, Charité-Universitätsmedizin Berlin, Berlin, Germany.
Förderung
- LEO Pharma A/S
- LEO Pharma Research Foundation
Zitieren
APA
Thaçi, D., Laquer, V., Lynde, C., Reich, A., Soong, W., Worm, M., Arlert, P., Blemings, A., Litman, T., Martel, B. C., Olesen, M., Sørensen, O. E., & Gooderham, M. (2026). Targeting IL-22RA1 with temtokibart: A novel approach in atopic dermatitis: Phase 2a monotherapy study results. Journal of Allergy and Clinical Immunology, 157(3), 666-676. https://doi.org/10.1016/j.jaci.2025.08.034
Vancouver
Thaçi D, Laquer V, Lynde C, Reich A, Soong W, Worm M, et al. Targeting IL-22RA1 with temtokibart: A novel approach in atopic dermatitis: Phase 2a monotherapy study results. Journal of Allergy and Clinical Immunology. 2026;157(3):666-676. doi:10.1016/j.jaci.2025.08.034
BibTeX
@article{Thai2026,
author = {Thaçi, Diamant and Laquer, Vivian and Lynde, Charles and Reich, Adam and Soong, Weily and Worm, Margitta and Arlert, Petra and Blemings, Allan and Litman, Thomas and Martel, Britta C and Olesen, Martin and Sørensen, Ole E and Gooderham, Melinda},
title = {Targeting IL-22RA1 with temtokibart: A novel approach in atopic dermatitis: Phase 2a monotherapy study results},
journal = {Journal of Allergy and Clinical Immunology},
year = {2026},
volume = {157},
number = {3},
pages = {666--676},
doi = {10.1016/j.jaci.2025.08.034}
}
EUVIMED